Display options
Share it on

Mol Clin Oncol. 2014 Sep;2(5):685-694. doi: 10.3892/mco.2014.299. Epub 2014 May 29.

Prognostic value of peripheral and local forkhead box P3.

Molecular and clinical oncology

Takeo Hasegawa, Hiroyuki Suzuki, Takumi Yamaura, Satoshi Muto, Naoyuki Okabe, Jun Osugi, Mika Hoshino, Mitsunori Higuchi, Kazuya Ise, Mitsukazu Gotoh

Affiliations

  1. Department of Regenerative Surgery, Fukushima Medical University, School of Medicine, Fukushima 960-1295, Japan.

PMID: 25054031 PMCID: PMC4106667 DOI: 10.3892/mco.2014.299

Abstract

Several types of immunosuppressive mechanisms in cancer patients have been reported to date. Regulatory T cells (Tregs), which express the master control transcription factor forkhead box P3 (FoxP3), are considered to play a major role in hampering antitumor immune response. However, the clinical significance of Tregs in patients with lung cancer has not been fully elucidated. The aim of this study was to investigate the clinical significance of Tregs in the peripheral blood and in resected cancer tissue specimens. We analyzed peripheral blood mononuclear cells (PBMCs) collected prior to surgery and resected specimens obtained from 67 patients with non-small-cell lung cancer (NSCLC). Peripheral Tregs (pTregs) were detected as CD4

Keywords: forkhead box P3; immunosuppression; immunotherapy; non-small-cell lung cancer; regulatory T cells

References

  1. Clin Cancer Res. 2007 Feb 1;13(3):902-11 - PubMed
  2. Clin Cancer Res. 2006 Sep 15;12(18):5423-34 - PubMed
  3. J Exp Med. 2005 Oct 3;202(7):885-91 - PubMed
  4. Clin Cancer Res. 2007 Apr 1;13(7):2075-81 - PubMed
  5. Annu Rev Immunol. 2007;25:267-96 - PubMed
  6. Eur J Immunol. 2005 Jun;35(6):1681-91 - PubMed
  7. J Immunol. 1995 Aug 1;155(3):1151-64 - PubMed
  8. Br J Cancer. 2006 Jan 30;94(2):275-80 - PubMed
  9. Immunity. 2005 Mar;22(3):329-41 - PubMed
  10. Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3355-60 - PubMed
  11. J Thorac Oncol. 2007 Aug;2(8):706-14 - PubMed
  12. Immunity. 2007 Jul;27(1):145-59 - PubMed
  13. Science. 2003 Feb 14;299(5609):1057-61 - PubMed
  14. Cancer Res. 2007 Jan 1;67(1):371-80 - PubMed
  15. Nat Med. 2004 Sep;10(9):909-15 - PubMed
  16. N Engl J Med. 2003 Jan 16;348(3):203-13 - PubMed
  17. J Clin Invest. 2003 Nov;112(9):1310-2 - PubMed
  18. Clin Cancer Res. 2003 Oct 1;9(12):4404-8 - PubMed
  19. Clin Dev Immunol. 2007;2007:89195 - PubMed
  20. J Exp Med. 2001 Sep 17;194(6):823-32 - PubMed
  21. Oncogene. 2008 Oct 6;27(45):5904-12 - PubMed
  22. Nat Rev Cancer. 2007 Nov;7(11):880-7 - PubMed
  23. CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90 - PubMed
  24. Cancer. 2006 Dec 15;107(12):2866-72 - PubMed
  25. Clin Cancer Res. 2005 Dec 1;11(23):8326-31 - PubMed
  26. J Thorac Oncol. 2011 Mar;6(3):432-8 - PubMed
  27. Clin Cancer Res. 2006 Jan 15;12(2):465-72 - PubMed
  28. Expert Opin Biol Ther. 2010 Jul;10(7):1019-35 - PubMed
  29. Pancreas. 2004 Jan;28(1):e26-31 - PubMed
  30. Clin Cancer Res. 2003 Feb;9(2):606-12 - PubMed
  31. Immunology. 2002 Sep;107(1):5-9 - PubMed
  32. Clin Cancer Res. 2008 Feb 15;14(4):1032-40 - PubMed
  33. Clin Cancer Res. 2008 Aug 15;14(16):5166-72 - PubMed
  34. Blood. 2008 Aug 1;112(3):610-8 - PubMed
  35. Cancer Res. 1999 Jul 1;59(13):3128-33 - PubMed
  36. Clin Lung Cancer. 2009 Sep;10(5):371-4 - PubMed
  37. J Cancer Res Clin Oncol. 2011 Sep;137(9):1337-42 - PubMed
  38. Oncol Rep. 2006 May;15(5):1315-9 - PubMed
  39. Cancer. 2010 Mar 15;116(6):1518-25 - PubMed
  40. Cancer Res. 2003 Apr 1;63(7):1555-9 - PubMed
  41. J Immunol. 2002 Sep 1;169(5):2756-61 - PubMed

Publication Types